|
1
|
GPCR interacting proteins (GIP).
|
Pharmacol Ther
|
2004
|
1.61
|
|
2
|
New sorting nexin (SNX27) and NHERF specifically interact with the 5-HT4a receptor splice variant: roles in receptor targeting.
|
J Cell Sci
|
2004
|
1.40
|
|
3
|
Neuronal 5-HT metabotropic receptors: fine-tuning of their structure, signaling, and roles in synaptic modulation.
|
Cell Tissue Res
|
2006
|
1.38
|
|
4
|
Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions.
|
Trends Pharmacol Sci
|
2008
|
1.37
|
|
5
|
Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach.
|
EMBO J
|
2002
|
1.35
|
|
6
|
GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation.
|
Trends Pharmacol Sci
|
2007
|
1.33
|
|
7
|
The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks.
|
FEBS Lett
|
2003
|
1.32
|
|
8
|
GPCR interacting proteins (GIPs) in the nervous system: Roles in physiology and pathologies.
|
Annu Rev Pharmacol Toxicol
|
2010
|
1.27
|
|
9
|
The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins.
|
J Biol Chem
|
2004
|
1.25
|
|
10
|
Co-assembly of two GluR6 kainate receptor splice variants within a functional protein complex.
|
Neuron
|
2005
|
1.24
|
|
11
|
G protein activation by serotonin type 4 receptor dimers: evidence that turning on two protomers is more efficient.
|
J Biol Chem
|
2011
|
1.21
|
|
12
|
Proteomic analysis of astrocytic secretion in the mouse. Comparison with the cerebrospinal fluid proteome.
|
J Biol Chem
|
2003
|
1.18
|
|
13
|
The serotonin transporter is an exclusive client of the coat protein complex II (COPII) component SEC24C.
|
J Biol Chem
|
2011
|
1.11
|
|
14
|
Inverse agonist and neutral antagonist actions of antidepressants at recombinant and native 5-hydroxytryptamine2C receptors: differential modulation of cell surface expression and signal transduction.
|
Mol Pharmacol
|
2007
|
1.10
|
|
15
|
Physical interaction of calmodulin with the 5-hydroxytryptamine2C receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling.
|
Mol Biol Cell
|
2008
|
1.08
|
|
16
|
Akt mediates the anti-apoptotic effect of NMDA but not that induced by potassium depolarization in cultured cerebellar granule cells.
|
Eur J Neurosci
|
2002
|
1.03
|
|
17
|
Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit.
|
J Neurochem
|
2006
|
1.03
|
|
18
|
PICK1 uncoupling from mGluR7a causes absence-like seizures.
|
Nat Neurosci
|
2008
|
1.03
|
|
19
|
Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine2C receptor desensitization and membrane stability.
|
Mol Biol Cell
|
2006
|
1.00
|
|
20
|
The proteomic analysis of mouse choroid plexus secretome reveals a high protein secretion capacity of choroidal epithelial cells.
|
Proteomics
|
2006
|
0.97
|
|
21
|
Motoneurons secrete angiogenin to induce RNA cleavage in astroglia.
|
J Neurosci
|
2012
|
0.97
|
|
22
|
5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia.
|
EMBO Mol Med
|
2012
|
0.95
|
|
23
|
Enhanced detection of CNS cell secretome in plasma protein-depleted cerebrospinal fluid.
|
J Proteome Res
|
2008
|
0.95
|
|
24
|
Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-HT4 receptor signalling.
|
EMBO J
|
2009
|
0.95
|
|
25
|
Identification of new proteins in follicular fluid of mature human follicles.
|
Electrophoresis
|
2002
|
0.94
|
|
26
|
Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death.
|
J Neurosci
|
2010
|
0.91
|
|
27
|
PACAP type I receptor transactivation is essential for IGF-1 receptor signalling and antiapoptotic activity in neurons.
|
EMBO J
|
2007
|
0.90
|
|
28
|
Shank3-Rich2 interaction regulates AMPA receptor recycling and synaptic long-term potentiation.
|
J Neurosci
|
2013
|
0.89
|
|
29
|
Difference in mass analysis using labeled lysines (DIMAL-K): a new, efficient proteomic quantification method applied to the analysis of astrocytic secretomes.
|
Mol Cell Proteomics
|
2005
|
0.89
|
|
30
|
A proteomic approach based on peptide affinity chromatography, 2-dimensional electrophoresis and mass spectrometry to identify multiprotein complexes interacting with membrane-bound receptors.
|
Biol Proced Online
|
2002
|
0.89
|
|
31
|
Constitutive activity of serotonin 2C receptors at G protein-independent signaling: modulation by RNA editing and antidepressants.
|
Mol Pharmacol
|
2010
|
0.88
|
|
32
|
Synergistic Regulation of Cytosolic Ca2+ Concentration by Adenosine and alpha1-Adrenergic Agonists in Mouse Striatal Astrocytes.
|
Eur J Neurosci
|
1991
|
0.86
|
|
33
|
5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10.
|
ACS Chem Neurosci
|
2012
|
0.86
|
|
34
|
Molecular and functional characterization of proteins interacting with the C-terminal domains of 5-HT2 receptors: emergence of 5-HT2 "receptosomes".
|
Biol Cell
|
2004
|
0.85
|
|
35
|
High performance two-dimensional gel electrophoresis using a wetting agent Tergitol NP7.
|
Proteomics
|
2002
|
0.85
|
|
36
|
GPCR-GIP networks: a first step in the discovery of new therapeutic drugs?
|
Curr Opin Drug Discov Devel
|
2004
|
0.85
|
|
37
|
5-HT6 Receptor: A New Player Controlling the Development of Neural Circuits.
|
ACS Chem Neurosci
|
2015
|
0.84
|
|
38
|
Disrupting 5-HT(2A) receptor/PDZ protein interactions reduces hyperalgesia and enhances SSRI efficacy in neuropathic pain.
|
Mol Ther
|
2010
|
0.84
|
|
39
|
CRMP2 tethers kainate receptor activity to cytoskeleton dynamics during neuronal maturation.
|
J Neurosci
|
2013
|
0.83
|
|
40
|
Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection.
|
Anal Biochem
|
2005
|
0.82
|
|
41
|
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
|
J Pharmacol Exp Ther
|
2011
|
0.81
|
|
42
|
Angiogenin induces modifications in the astrocyte secretome: relevance to amyotrophic lateral sclerosis.
|
J Proteomics
|
2013
|
0.80
|
|
43
|
Calcineurin interacts with the serotonin transporter C-terminus to modulate its plasma membrane expression and serotonin uptake.
|
J Neurosci
|
2013
|
0.79
|
|
44
|
Quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic agonists.
|
Mol Cell Proteomics
|
2014
|
0.79
|
|
45
|
The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors.
|
Int J Neuropsychopharmacol
|
2010
|
0.79
|
|
46
|
Identification of PDZ ligands by docking-based virtual screening for the development of novel analgesic agents.
|
Bioorg Med Chem Lett
|
2013
|
0.77
|
|
47
|
Quantitative proteomic analysis reveals protein expression changes in the murine neuronal secretome during apoptosis.
|
J Proteomics
|
2012
|
0.77
|
|
48
|
Structure-based design of PDZ ligands as inhibitors of 5-HT(2A) receptor/PSD-95 PDZ1 domain interaction possessing anti-hyperalgesic activity.
|
ACS Chem Biol
|
2013
|
0.76
|
|
49
|
Synthesis and evaluation of bidentate ligands designed to interact with PDZ domains.
|
Bioorg Med Chem
|
2011
|
0.76
|
|
50
|
Disruption of 5-HT2A receptor-PDZ protein interactions alleviates mechanical hypersensitivity in carrageenan-induced inflammation in rats.
|
PLoS One
|
2013
|
0.75
|
|
51
|
Techniques for studying inverse agonist activity of antidepressants at recombinant nonedited 5-HT(₂C-INI) receptor and native neuronal 5-HT(₂C) receptors.
|
Methods Enzymol
|
2010
|
0.75
|
|
52
|
[Proteomic profiling: the potential of Seldi-Tof for the identification of new cancer biomarkers].
|
Bull Cancer
|
2005
|
0.75
|
|
53
|
[When two molecules involved in the regulation of mood meet: mutual modulation of the serotonin transporter and neuronal NO-synthase].
|
Med Sci (Paris)
|
2007
|
0.75
|
|
54
|
[The mTOR pathway: a new target for treating cognitive deficits of schizophrenia?].
|
Med Sci (Paris)
|
2013
|
0.75
|